Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy

Chinese PLA General Hospital100 enrolled

Overview

This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma

This prospective, single-centre, observational cohort study is disigned to enroll 100 newly diagnosed lymphoma patients who met the inclusion and exclusion criteria to monitor the onset of atrial fibrillation and other arrhythmias during chemotherapy by using wearable ECG recorder, and to evaluate the incidence of atrial fibrillation and related risk factors.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Atrial Fibrillation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. At least 18 years old; 2. Concurrent chemotherapy on patients with new-onset lymphoma: chemotherapy regimens containing anthracyclines; 3. The subject voluntarily signed the informed consent. Exclusion Criteria: 1. With heart failure, acute stroke or acute coronary syndrome within 3 months before admission 2. With Atrial fibrillation on admission 3. Patient after pacemaker surgery 4. With mental illness or mentally disabled 5. Patients that the investigator considers as unsuitable for this test

Locations (1)

General hospital of PLA

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Incidence

Incidence of atrial fibrillation after chemotherapy

Time frame: 1 year after the first course of chemotherapy

Central Contacts

Yundai Chen

CONTACT

+86 01055499135 cyundai@vip.163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.